Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

TAR - BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue

Company: BerGenBio Date: 2025-08-04 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.html) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue

# BerGenBio ASA: Approval of the merger plan and the fully underwritten rights issue

Bergen, 4 August 2025: Reference is made to the joint stock exchange  

announcement made on 30 June 2025 by BerGenBio ASA (the "Company") and  

Oncoinvent ASA ("Oncoinvent") regarding the contemplated combination of the  

Company, Oncoinvent and BerGenBio Norge AS though a statutory triangular merger  

(the "Merger").  

  

An extraordinary general meeting of the Company was held on 12:00 hours (CEST)  

today by electronic means through Lumi AGM. All items on the agenda were  

resolved in accordance with the board of directors' and the nomination  

committee's proposals, including, but not limited to, approval of the merger  

plan dated 30 June 2025 (the "Merger Plan") and the fully underwritten rights  

issue in the Company to raise gross proceeds of NOK 130 million.  

  

As announced by Oncoinvent today, the Merger Plan has been approved by the  

extraordinary general meeting of Oncoinvent. As a consequence, the decision to  

approve the Merger will now be filed with the Norwegian Register of Business  

Enterprises. Completion of the Merger remains subject to customary terms and  

conditions, as further described in the Merger Plan and the joint stock exchange  

announcement made on 30 June 2025.  

  

The minutes from the extraordinary general meeting are attached hereto and will  

also be made available on the Company's website www.bergenbio.no.  

  

For further information regarding the Merger and the complete terms and  

conditions for the Merger, please see the Merger Plan with appendices available  

on www.bergenbio.no.  

  

For further information, please contact:  

  

Olav Hellebø, CEO, BerGenBio ASA, ir@bergenbio.com  

  

Rune Skeie, CFO, BerGenBio ASA, rune.skeie@bergenbio.com  

  

This information is subject to the disclosure requirements pursuant to Section 5  

\-12 of the Norwegian Securities Trading Act.